AstraZeneca: Datopotamab Deruxtecan Biologics License Application Accepted in the US for Patients With Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer
February 20, 2024
February 20, 2024
WILMINGTON, Delaware, Feb. 20 -- AstraZeneca, a biopharmaceutical company, issued the following news release:
AstraZeneca and Daiichi Sankyo's Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted in the US for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) who have received prior systemic therapy. The Prescription Drug User Fee Act date, the Food and Drug Administration (FDA) a . . .
AstraZeneca and Daiichi Sankyo's Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted in the US for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) who have received prior systemic therapy. The Prescription Drug User Fee Act date, the Food and Drug Administration (FDA) a . . .